Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

Acute toxicity: oral
LD50 of ZMB2 is 800 mg/kg (Bioscience Incorporated, 1977).
Acute toxicity: dermal
LD50 of ZMB2 is >2000 mg/kg bodyweight (Safepharm, 2002).
Acute toxicity: inhalation
LC50 of ZMB2 is >2.12 mg/L (Safepharm, 2003).

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
Value:
800 mg/kg bw
Quality of whole database:
2 (reliable with restrictions)

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LC50
Value:
2 120 mg/m³ air
Quality of whole database:
1 (reliable without restriction)

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw
Quality of whole database:
1 (reliable without restriction)

Additional information

Acute toxicity - oral:

Key study:

ZMB2, when studied in male albino rats has an acute oral LD50 of 3.2 ml/kg with 19/20 Confidence Limits of from 2.5 to 4.3 ml/kg or 0.8g/kg (800 mg/kg) with 19/20 Confidence Limits of 0.63 to 1.08 g/kg (Biosearch Incorporated, 1977).

Supporting study:

In an OECD 401 study, not conducted to GLP, the acute oral LD50 to rats of ZMB2 is 390 mg/kg bw (rat, male) (Loeser, 1978).

Acute toxicity - dermal:

The acute dermal median lethal dose (LD50) of ZMB2 in the Sprague-Dawley CD strain rat was found to be greater than 2000 mg/kg bodyweight (Safepharm, 2002).

Acute toxicity - inhalation:

No deaths occurred in a group of ten rats exposed to a mean achieved atmosphere concentration of 2.12 mg/L. It was therefore considered that the acute inhalation median lethal concentration of ZMB2 in the Sprague-Dawley Crl:CD (SD) IGS BR strain rat, is greater than 2.12 mg/L (Safepharm, 2003).


Justification for selection of acute toxicity – oral endpoint
Well conducted study, equivalent or similar to OECD Guideline 401 (Acute Oral Toxicity).

Justification for selection of acute toxicity – inhalation endpoint
Well conducted study in accordance with OECD Guideline under GLP conditions. No additional studies available.

Justification for selection of acute toxicity – dermal endpoint
Well conducted study in accordance with OECD Guideline under GLP conditions. No additional studies available.

Justification for classification or non-classification

Acute toxicity - oral:

The LD50 of ZMB2 is 800 mg/kg, therefore, according to Regulation EC No. 1272/2008 on classification, labelling and packaging (CLP) of substances and mixtures the substance is classified as Category 4 (Warning) H302: Harmful if swallowed.

Acute toxicity - dermal:

The LD50 of ZMB2 is >2000 mg/kg, therefore, according to Regulation EC No. 1272/2008 on classification, labelling and packaging (CLP) of substances and mixtures the substance is not classified.

Acute toxicity - inhalation:

The LD50 of ZMB2 is >2.12 mg/L, therefore, according to Regulation EC No. 1272/2008 on classification, labelling and packaging (CLP) of substances and mixtures the substance is classified as Category 4 (Warning) H332: Harmful if inhaled.

.